Ceramides and phospholipids in plasma extracellular vesicles are associated with high risk of major cardiovascular events after carotid endarterectomy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
20
08
2021
accepted:
28
02
2022
entrez:
2
4
2022
pubmed:
3
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Ceramides and phosphatidylcholines (PCs) are bioactive lipids and lipid bilayer membrane components. Distinct ceramides/PCs (ratios) predict cardiovascular outcome in patients with coronary artery disease. Extracellular vesicles (EVs) are proposed biomarkers for cardiovascular disease and contain ceramides/PCs. Ceramides/PCs have not been studied in patients undergoing carotid endarterectomy (CEA) nor in EVs. We therefore investigated whether levels of ceramides/PCs in plasma and EVs are associated with postoperative risk of major adverse cardiovascular events (MACE) following CEA. In 873 patients undergoing CEA of the Athero-Express biobank, we quantitatively measured seven ceramides/PCs in preoperative blood samples: Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0), Cer(d18:1/24:1), PC(14:0/22:6), PC(16:0/16:0) and PC(16:0/22:5) in plasma and two plasma EV-subfractions (LDL and TEX). We analyzed the association of ceramides, PCs and their predefined ratios with the three-year postoperative risk of MACE (including stroke, myocardial infarction and cardiovascular death). A total of 138 patients (16%) developed MACE during the three-year follow-up. In the LDL-EV subfraction, higher levels of Cer(d18:1/24:1) and Cer(d18:1/16:0)/PC(16:0/22:5) ratio were significantly associated with an increased risk of MACE (adjusted HR per SD [95% CI] 1.24 [1.01-1.53] and 1.26 [1.04-1.52], respectively). In the TEX-EV subfraction, three ratios Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/18:0)/Cer(d18:1/24:0) and Cer(d18:1/24:1)/Cer(d18:1/24:0) were positively associated with MACE (adjusted HR per SD 1.34 [1.06-1.70], 1.24 [1.01-1.51] and 1.31 [1.08-1.58], respectively). In conclusion, distinct ceramides and PCs in plasma EVs determined in preoperative blood were independently associated with an increased 3-year risk of MACE after CEA. These lipids are therefore potential markers to identify high-risk CEA patients qualifying for secondary preventive add-on therapy.
Identifiants
pubmed: 35365690
doi: 10.1038/s41598-022-09225-6
pii: 10.1038/s41598-022-09225-6
pmc: PMC8975809
doi:
Substances chimiques
Ceramides
0
Phospholipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5521Informations de copyright
© 2022. The Author(s).
Références
Diabetes Metab Res Rev. 2015 Oct;31(7):734-44
pubmed: 25959529
Atherosclerosis. 2008 Feb;196(2):497-504
pubmed: 17963772
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Nat Rev Endocrinol. 2017 Feb;13(2):79-91
pubmed: 27767036
Eur J Anaesthesiol. 2015 Feb;32(2):88-105
pubmed: 25058504
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Am Coll Cardiol. 2019 Jul 2;73(25):3271-3280
pubmed: 31248548
Nat Rev Cardiol. 2017 May;14(5):259-272
pubmed: 28150804
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Sci Rep. 2020 Jul 23;10(1):12257
pubmed: 32704130
Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2424-2430
pubmed: 27765765
PLoS One. 2016 Jan 28;11(1):e0148073
pubmed: 26820481
Eur Heart J. 2016 Jul 01;37(25):1967-76
pubmed: 27125947
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Biochem Pharmacol. 2019 Dec;170:113677
pubmed: 31647926
Diabetes Care. 2020 Sep;43(9):2183-2189
pubmed: 32527800
Cell Metab. 2014 Oct 7;20(4):687-95
pubmed: 25295789
JAMA. 2020 Apr 14;323(14):1353-1368
pubmed: 32219386
Int J Mol Sci. 2017 Dec 29;19(1):
pubmed: 29286309
J Cardiovasc Transl Res. 2021 Feb;14(1):140-149
pubmed: 32212040
Cochrane Database Syst Rev. 2021 Dec 21;12:CD013139
pubmed: 34931303
Circulation. 2017 May 23;135(21):2028-2040
pubmed: 28280233
Int J Cardiol. 2013 Oct 3;168(3):2358-63
pubmed: 23484740
N Engl J Med. 1991 Aug 15;325(7):445-53
pubmed: 1852179
N Engl J Med. 1998 Nov 12;339(20):1415-25
pubmed: 9811916
J Vasc Surg. 2007 Feb;45(2):289-96; discussion 296-7
pubmed: 17264005
Circulation. 2010 May 4;121(17):1941-50
pubmed: 20404256
J Am Coll Cardiol. 2011 Nov 8;58(20):2047-67
pubmed: 22051327
Lancet. 2010 Sep 25;376(9746):1074-84
pubmed: 20870099
N Engl J Med. 2020 Nov 5;383(19):1838-1847
pubmed: 32865380
Atherosclerosis. 2011 Oct;218(2):369-77
pubmed: 21868015
Stroke. 2012 May;43(5):1273-8
pubmed: 22442175
Circulation. 2016 Nov 8;134(19):1419-1429
pubmed: 27682883
Eur Heart J. 2020 Jan 14;41(3):371-380
pubmed: 31209498
Eur Stroke J. 2018 Mar;3(1):57-65
pubmed: 29900410
PLoS One. 2013 May 14;8(5):e62968
pubmed: 23690971
J Clin Endocrinol Metab. 2014 Jan;99(1):E45-52
pubmed: 24243630
Eur J Epidemiol. 2004;19(12):1127-33
pubmed: 15678794
JCI Insight. 2018 Sep 6;3(17):
pubmed: 30185661
N Engl J Med. 2020 May 21;382(21):1994-2004
pubmed: 32222135
Circ Res. 2020 Jan 3;126(1):112-128
pubmed: 31895658
PLoS One. 2014 Jan 17;9(1):e85724
pubmed: 24465667
Clin Chem. 2012 Oct;58(10):1408-17
pubmed: 22952348
Atherosclerosis. 2015 Dec;243(2):560-6
pubmed: 26523994
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
Lancet. 2004 May 8;363(9420):1491-502
pubmed: 15135594
Lancet. 1998 May 9;351(9113):1379-87
pubmed: 9593407
Atherosclerosis. 2018 Feb;269:159-165
pubmed: 29366988